TickerFacts.

Sol-Gel Technologies Ltd. (SLGL): Revenue

Annual figures by period end, from SEC filings.

$19.39M
Year ended 2025-12-31
+70.9%
3-year compound annual growth
+17.2%
5-year compound annual growth
$31.27M2017-12-31: $174.0K2018-12-31: $129.0K2019-12-31: $22.90M2020-12-31: $8.77M2021-12-31: $31.27M2022-12-31: $3.88M2023-12-31: $1.55M2024-12-31: $11.54M2025-12-31: $19.39M$19.39M
2017-12-31 Revenue (USD) 2025-12-31
Period endedRevenueChange YoYSource filing
2025-12-31$19.39M+68.0%2026-03-19, From 2025-01-01
2024-12-31$11.54M+642.5%2026-03-19, From 2024-01-01
2023-12-31$1.55M-60.0%2026-03-19, From 2023-01-01
2022-12-31$3.88M-87.6%2025-04-29, From 2022-01-01
2021-12-31$31.27M+256.5%2024-03-13, From 2021-01-01
2020-12-31$8.77M-61.7%2023-03-10, From 2020-01-01
2019-12-31$22.90Mn/m2022-04-07, From 2019-01-01
2018-12-31$129.0K-25.9%2021-03-04, From 2018-01-01
2017-12-31$174.0Kn/a2020-03-24, From 2017-01-01

Revenue at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedRevenueChange YoY
Sol-Gel Technologies Ltd. (SLGL)2025-12-31$19.39M+68.0%
Evofem Biosciences, Inc. (EVFM)2025-12-31$20.18M+4.2%
Scynexis Inc (SCYX)2025-12-31$20.60M+449.9%
CASI Pharmaceuticals, Inc. (CASIF)2025-12-31$20.71M-27.4%
NewAmsterdam Pharma Co N.V. (NAMS)2025-12-31$22.50M-50.6%
uniQure N.V. (QURE)2025-12-31$16.10M-40.6%
Alumis Inc. (ALMS)2025-12-31$24.05Mn/a
Entrada Therapeutics, Inc. (TRDA)2025-12-31$25.42M-87.9%
Opus Genetics, Inc. (IRD)2025-12-31$14.20M+29.1%

Compare SLGL, EVFM, SCYX, CASIF side by side · Screen every company in Pharmaceutical Preparations ↗